Targeting BRAF V600E Mutations in Metastatic Colorectal Cancer

H&O How common is BRAF V600E–mutated colorectal cancer (CRC)? SK BRAF V600E mutations occur in approximately 5% to 7% of patients with metastatic CRC. That percentage […]

The Emerging Role of Antibody-Drug Conjugates in Metastatic Colorectal Cancer

H&O How well is colorectal cancer (CRC) suited to antibody-drug conjugate (ADC) therapy, in comparison with other solid tumors? JS It has been historically challenging to […]

Treatment Deintensification in Locally Advanced Rectal Cancer: When Less Is More

H&O Why is it so important to determine which components of treatment can be omitted in patients with locally advanced rectal cancer? AC The treatment modalities […]

The Emerging Role of Immunotherapy-Based Strategies in Nonmetastatic Colorectal Cancer

H&O What makes immunotherapy an appealing option for patients with nonmetastatic colorectal cancer (CRC)? MC Immunotherapy has become important because it is more effective than chemotherapy […]

EGFR Inhibitor Rechallenge in Metastatic Colorectal Cancer

H&O How often do patients with colorectal cancer (CRC) develop metastatic disease? JG Most CRC patients present with stage 1, 2, or 3 disease, with only […]

The Role of Antiangiogenesis Agents in Refractory Metastatic Colorectal Cancer

H&O What are the standard treatment options for patients with refractory metastatic colorectal cancer (CRC)? SK Patients with refractory metastatic CRC typically have already received chemotherapy […]

The Use of Immunotherapy in Metastatic Microsatellite-Stable Colorectal Cancer

H&O What percentage of cases of metastatic colorectal cancer (CRC) fall into the microsatellite-stable (MSS) category? CL Approximately 95% to 96% of patients with metastatic CRC […]

The Emerging Role of KRAS G12C Inhibitors in the Treatment of Locally Advanced or Metastatic Colorectal Cancer

H&O How common are KRAS G12C mutations in locally advanced or metastatic colorectal cancer? KC RAS mutations overall are quite common in colorectal cancer (CRC) and […]

Who Is a Candidate for Nonoperative Management of Early-Stage Rectal Cancer?

H&O What is standard treatment for early-stage rectal cancer? CH Surgery is the standard treatment for early-stage rectal cancer. In patients with T1N0 disease, the standard […]

Sequencing Strategies in the Management of Metastatic Colorectal Cancer With HER2 Amplification

H&O How common is HER2 amplification in metastatic colorectal cancer (CRC)? KR HER2 amplification is seen in approximately 2% to 3% of unselected patients with CRC. […]

Emerging Phase 3 Data in Relapsed/Refractory Metastatic Colorectal Cancer

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 Richard Goldberg, MD Interim Division Director of Medical Oncology Physician-in-Chief, OSUCCC-James Cancer Hospital […]

What Should We Tell Our Patients With Colorectal Cancer About Diet, Supplements, and Lifestyle?

Jeffrey A. Meyerhardt, MD, MPH Associate Professor, Department of Medicine Harvard Medical School Clinical Director, Gastrointestinal Cancer Center Dana-Farber Cancer Institute Boston, Massachusetts H&O What would […]

Stool DNA Testing: A New, Noninvasive Option for Colorectal Cancer Screening

Clinical Advances in Hematology & Oncology July 2015, Volume 13, Issue 7 David A. Ahlquist, MD Professor of Medicine Mayo Clinic Rochester, Minnesota H&O What […]